NCT01266577 Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
| NCT ID | NCT01266577 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Mental Health (NIMH) |
| Condition | Brain Mapping |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2011-01-27 |
| Primary Completion | 2027-10-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2011-01-27 with a primary completion date of 2027-10-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: \- Magnetic resonance imaging (MRI) is a widely used scanning technique to obtain images of the human body and evaluate activity in the brain. A particular MRI method called magnetic resonance spectroscopy (MRS) can be used to study brain chemistry as well, which may help researchers who are studying new treatments for psychiatric illnesses. Researchers are interested in improving current MRI and MRS techniques, as well as developing new MRI and MRS techniques to view and measure brain chemicals and brain activity. Objectives: \- To implement, develop, and optimize brain chemistry imaging techniques using magnetic resonance imaging and magnetic resonance spectroscopy. Eligibility: \- Healthy individuals between 18 and 65 years of age. Design: * This study will involve a screening visit and a scanning visit at the National Institutes of Health Clinical Center. * Participants will be screened with a full medical and physical examination, blood and urine tests, and neurological testing. * During the second visit, participants will have an MRI scan of the brain. (Participants who have received an MRI within the past year will not need to have a second one; the images of the previous scan will be used for this study.) All participants will then have an MRS scan using the same scanning equipment.
Eligibility Criteria
* INCLUSION CRITERIA: * 18-65 years of age * able to give written informed consent * healthy based on medical history and physical exam * enrolled in Protocol 01-M-0254 or Protocol 17-M-0181 EXCLUSION CRITERIA: * Any current Axis 1 diagnosis * Clinically significant laboratory abnormalities * Positive HIV test * Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan. * History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury * Inability to lie flat on camera bed for about two and a half hours * Pregnant or breastfeeding * Current substance use disorder based on DSM-5 * NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
Contact & Investigator
Li An, Ph.D.
PRINCIPAL INVESTIGATOR
National Institute of Mental Health (NIMH)
Frequently Asked Questions
Who can join the NCT01266577 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Brain Mapping. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01266577 currently recruiting?
Yes, NCT01266577 is actively recruiting participants. Contact the research team at johnsonchri@mail.nih.gov for enrollment information.
Where is the NCT01266577 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT01266577 clinical trial?
NCT01266577 is sponsored by National Institute of Mental Health (NIMH). The principal investigator is Li An, Ph.D. at National Institute of Mental Health (NIMH). The trial plans to enroll 300 participants.